RxDoctor Payments Data

Craig Snyder, MD

Interventional Cardiology · Edison, NJNPI 1427008945

Payments from drug & device makers

$3,142in general payments, 2019–2025

Across 167 payments — averaging $18.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$676
  • Abbott$270
  • E.r. Squibb & Sons, L.L.C.$243
  • Heartflow, Inc.$212
  • Novo Nordisk$195
  • Pfizer$168
  • plus $1K from 24 others

What the payments were for

  • Food & beverage$3,142100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,142 in reported general payments places this provider in the 25th percentile of 166 interventional cardiology providers in New Jersey.

See all interventional cardiology providers in New Jersey

Medicare billing

Part B allowed, 2024
$394,960
Medicare patients
1,115
Services billed
4,126

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban238$276,061
MultaqDronedarone Hcl53$100,467
EntrestoSacubitril/Valsartan69$81,817
XareltoRivaroxaban48$76,878
JardianceEmpagliflozin37$58,246
FarxigaDapagliflozin Propanediol47$54,273
BrilintaTicagrelor42$38,851
Repatha SureclickEvolocumab31$31,115
OzempicSemaglutide19$24,387
JanumetSitagliptin Phos/Metformin Hcl23$21,648
JanuviaSitagliptin Phosphate16$16,514
Nebivolol Hcl141$9,506
Valsartan204$6,006
Amlodipine-ValsartanAmlodipine Besylate/Valsartan88$5,908
Metoprolol Succinate375$5,463

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$168$276,061238 claims
Sanofi-aventis U.S. LLCMultaq$108$100,46753 claims
AstraZenecaFarxiga, Brilinta$90$93,12489 claims
NovartisEntresto$78$81,81769 claims
Johnson & JohnsonXarelto$83$76,87848 claims
Boehringer IngelheimJardiance$91$58,24637 claims
MerckJanumet, Januvia$12$38,16239 claims
Novo NordiskOzempic$195$24,38719 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 166 interventional cardiology providers in New Jersey.

Other interventional cardiology in Edison

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →